Salarius Pharmaceuticals prices $7 million public offering

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) announced the pricing of an underwritten public offering for gross proceeds of approximately $7 million before deducting underwriting discounts and commissions and other offering expenses.

The offering comprises 2,514,335 shares of common stock and pre-funded warrants to purchase 2,152,331 shares of common stock, each with accompanying Series A and Series B warrants to purchase up to 4,666,666 shares of common stock respectively. The combined public offering price per share of common stock and accompanying warrants is $1.50, while the combined price per pre-funded warrant and accompanying warrants is $1.4999.

Ladenburg Thalmann & Co. Inc. is serving as sole book-running manager for the offering. The closing is expected to occur on or about November 12, 2025, subject to satisfaction of closing conditions, including consummation of the company's proposed business combination transaction with Decoy Therapeutics Inc.

Salarius has granted the underwriter a 45-day option to purchase up to an additional 699,999 shares of common stock and/or 699,999 Series A warrants and/or 699,999 Series B warrants at their respective public offering prices, less underwriting discounts and commissions.

The company expects to use net proceeds to advance clinical development of Salarius' and Decoy's research and development programs, pay off certain of Decoy's outstanding promissory notes, and for general corporate purposes including working capital, research and development, and capital expenditures.

Each pre-funded warrant has an exercise price of $0.0001 and is immediately exercisable until exercised in full. The Series A and Series B warrants each have an exercise price of $1.50. Series A warrants are exercisable for five years from issuance, while Series B warrants are exercisable for one year.

The securities are being offered pursuant to a registration statement on Form S-1 that became effective November 10, 2025, according to the company's statement.

You May Also Be Interested In

• Jupiter Neurosciences prices $2M registered direct offering of shares
• Real and RE/MAX Holdings set Aug. 24 merger closing date
• EShallGo closes $1.75M registered direct offering at $1 per share